指南与共识乳腺癌

撒哈拉以南非洲ABC-DO队列中非转移性乳腺癌患者的治疗指南一致性、治疗启动与放弃:一项前瞻性队列研究

Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer-Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa: a prospective cohort study.
指南 / 共识 · Lancet Oncol · 2022-05-09

该前瞻性队列研究在撒哈拉以南非洲五国八家医院招募非转移性乳腺癌女性,分析手术、放疗和系统治疗的启动、完成与放弃情况。中位随访5.2年,仅68%接受手术,多模式治疗启动比例在局部肿瘤与局部晚期肿瘤间存在差异,化疗和内分泌治疗的完成率低,各国治疗差异显著。作者指出需改善治疗可及性与完成度。

要点

  • 1716例非转移性乳腺癌女性中,1163例(68%)接受了乳腺癌手术。
  • 局部肿瘤患者多模式治疗联合放疗启动率为36%,局部晚期为23%。
  • 需要化疗的1530例中,1013例(66%)启动新辅助化疗或手术后3个月内手术,仅359例(35%)充分完成。

核心结论

  • 高比例的非转移性乳腺癌患者未启动、未完全完成或放弃了手术、系统治疗、放疗或适当组合的治疗,凸显撒哈拉以南非洲需改善治疗可及性和完成度以潜在预防过早乳腺癌死亡。

研究设计与样本

  • ABC-DO前瞻性队列研究,2014年9月10日至2017年12月31日在纳米比亚、尼日利亚、乌干达、南非和赞比亚五国的八家医院招募年龄≥18岁的新诊断浸润性乳腺癌女性。
  • 从2313例招募女性中,2226例经组织学或临床确诊乳腺癌,排除378例转移性疾病、37例流行病例(基线前>2年诊断)、82例未知TNM分期和13例南非白人/亚洲女性后,最终分析1716例初始表现为非转移性(M0)的女性。
  • 通过病历、诊断后6个月自报随访问卷、每3个月随访电话和基线问卷获取手术、放疗和系统治疗数据,分析治疗模式及联合方案的启动、完成和放弃情况。

主要发现

  • 中位随访5.2年(IQR 4.6-5.9),1716例女性中1163例(68%)接受了乳腺癌手术。
  • 局部肿瘤患者中,370例(36%)启动了手术和系统治疗联合放疗的多模式治疗,386例(38%)启动了不含放疗的多模式治疗;局部晚期肿瘤患者中,分别为156例(23%)和167例(24%)。
  • 需要化疗的1530例患者中(排除基线后6个月内死亡的105例),1013例(66%)在基线后3个月内启动了新辅助化疗或手术,其中359例(35%)充分完成,284例(28%)勉强完成,200例(20%)放弃,151例(15%)未知;19例(2%)在化疗启动后6个月内死亡。
  • 内分泌治疗适用的1375例女性中,920例启动治疗,367例(40%)持续至少3年。
  • 所有治疗方案在国家特定组间存在显著治疗差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Comprehensive breast cancer management is essential to achieve high breast cancer survival; however, detailed reports of the treatment regimens received by patients are scarce in sub-Saharan Africa where survival is low. We aimed to examine treatment initiation, guideline concordance, and abandonment in patients with non-metastatic breast cancer in sub-Saharan Africa from the African Breast Cancer-Disparities in Outcomes (ABC-DO) prospective cohort. METHODS: The ABC-DO prospective cohort study recruited women (aged ≥18 years) with newly diagnosed invasive breast cancer in eight hospitals across five sub-Saharan African countries (Namibia, Nigeria, Uganda, South Africa, and Zambia). We analysed treatments received by women who were classified as non-metastatic (M0) at the initial presentation. Data on surgery, radiotherapy, and systemic therapies were obtained from medical records and a self-reported follow-up questionnaire at 6 months after the diagnosis, follow-up calls every 3 months, and a baseline questionnaire. Initiation, completion, and abandonment of treatment modalities and combined therapy regimens were examined overall, by country-specific groups, and by clinical factors relevant for guideline-based treatment. FINDINGS: Of 2313 women recruited into the ABC-DO study between Sept 10, 2014, and Dec 31, 2017, 2226 had histologically or clinically confirmed breast cancer. Of these 2226 women, 510 were excluded from the present analysis because 378 had metastatic disease, 37 were prevalent cases (defined as those previously diagnosed with breast cancer >2 years before baseline), 82 had unknown TNM stage, and 13 were White or Asian women in South Africa (number was too small for analysis). After a median follow-up of 5·2 years (IQR 4·6-5·9), 1163 (68%) of 1716 women underwent breast cancer surgery. Surgery and systemic therapy (ie, multimodality treatment) with radiotherapy was initiated in 370 (36%) of 1028 women with localised tumours versus 156 (23%) of 688 women with locally advanced tumours, whereas multimodality treatment without radiotherapy was initiated in 386 (38%) versus 167 (24%) women, respectively. Of 1530 patients requiring chemotherapy (which excludes 105 who died within 6 months after baseline), 1013 (66%) initiated treatment of neoadjuvant chemotherapy or surgery within 3 months after baseline, which was adequately completed by 359 (35%) of 1013 women, marginally completed by 284 (28%), abandoned by 200 (20%), and unknown in 151 (15%). 19 (2%) women died within 6 months after chemotherapy initiation. Of 1375 women in whom endocrine therapy was indicated, this treatment was initiated in 920, and lasted at least 3 years in 367 (40%) women. Treatment disparities between country-specific groups were substantial for all therapy regimens. INTERPRETATION: A high proportion of patients with non-metastatic breast cancer did not initiate, did not fully complete, or abandoned treatment with surgery, systemic therapy, radiotherapy, or an appropriate combination of these, highlighting the need for improved treatment access and completion in sub-Saharan Africa to potentially prevent premature breast cancer deaths. FUNDING: National Institutes of Health (National Cancer Institute), Susan G Komen, and the International Agency for Research on Cancer.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Foerster M, McCormack V, Anderson BO, et al. Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer-Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa: a prospective cohort study. Lancet Oncol. 2022. PMID: 35550274. doi:10.1016/S1470-2045(22)00198-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。